Insight Brief
January 04, 2017

Companion Diagnostic Development: Current trends and recommendations

Examining the trends in personalized medicine sheds light on ways to create successful partnerships between sponsors, laboratories, and manufacturers of in-vitro diagnostic products (IVDs) to develop more efficiently stand-alone diagnostics, companion diagnostics (CDx), and complementary diagnostics. This is particularly relevant in light of the paradigm shift on the horizon for developing and ensuring reimbursement of such personalized medicine solutions with new technologies. Download this insight brief now to learn six strategies for success when developing your companion diagnostic.

Patrice Hugo, PhD, Chief Scientific Officer
Richard Heichemer, MS, MBA, Scientific Advisor, Companion Diagnostics

Related Services:
Are You Ready for the In Vitro Diagnostics Regulation (IVDR)?

Recommendations on meeting the IVDR

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Central Laboratory Considerations for Deploying a Global Companion Diagnostics Solution

World CDx Europe 2018

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Read More